|
|
 |
|
Viewing report
|
|
|
|
Cystic Fibrosis: Will New Agents Emerge as First-Line Therapies?
Decision Resources, Inc., June 2008, Pages: 39
The cystic fibrosis (CF) market is poised for significant change. The next generation of CF treatments all target the central mechanism responsible for organ damage in CF. These agents, as one thought leader states, “represent the closest we have come to a cure for CF” and will almost certainly bring about a change in the treatment algorithm of the disease. As a result, new market leaders will emerge, and current first-line therapies will find themselves relegated to second- or third-line options.
Get the Answers You Need to Shape Your Strategy
Physicians use a variety of medications and non-pharmacological treatments to address the needs of:
-CF patients. What are the strengths and weaknesses of these treatments? Which work best in specific subpopulations? Do thought leaders believe these treatments will still have a role in the treatment algorithm over the next five to ten years?
-Several drugs with trusted and novel mechanisms of action are in development for CF.
What new agents are in development? What are thought leaders’ opinions of the potential of these agents in the treatment of CF? What impact will these agents have on treatment algorithms and the CF market?
-Emerging agents target the central mechanism responsible for organ damage in CF and have the potential to be disease modifying rather than just treating symptoms. What unmet needs remain in drug development? Will the formulations of these emerging therapies improve patient compliance? What more is required to effectively treat the paediatric subpopulation?
Overview of - CF: disease development, symptoms, complications, and methods for diagnosis.
- Epidemiology: disease defi nition; incidence by race; growth in the number of prevalent cases.
- Current therapies: mucolytics, antibiotics, pancreatic enzyme replacement therapy, as well as thought leaders’ opinions on where these agents fi t into the treatment algorithm.
- Emerging therapies: strengths and weaknesses of agents in development; novel mechanisms of action; an analysis of market position for these agents.
- CF market: details on the 2007 market and prescribing trends.
- Outlook: the impact of novel agents on the CF market.
- Orphan Disease Series: As competition increases in larger disease states, companies are turning to orphan diseases that offer substantial pricing advantages and lower regulatory hurdles because of high unmet need. The Orphan Disease Series provides critical market information, including disease prevalence, profi les of marketed and emerging agents, and insight into the prescribing choices of disease specialists for diseases with smaller patient populations. These reports will help you to maximize the potential of your agents in these challenging markets, including the regulatory
benefi ts available and the potential for partnership with charitable organizations.
Customers who bought this item also bought
Will the Approval of New Agents Redefine the Cystic Fibrosis Market?
R&D Trends: Cystic Fibrosis - New drugs tackle both cause and effect
Delivering Drugs by Inhalation
Cystic Fibrosis
Current Treatments, Unmet Needs, and Opportunities in Treating Pediatric Crohn’s Disease
Do Emerging Therapies Offer Better Treatment Options for Hemophilia Patients?
Molecular Diagnostics - Technologies, Markets and Companies
Emerging Medical Technologies Spotlight, A Report Of Investment & Partnering Opportunities, 2011
Pulmonary Inhalers & Systemic Drug Delivery: Devices, Drugs, Therapeutics, Market Factors & Forecasts
Juvenile Idiopathic Arthritis - Disease-Subtype Heterogeneity Drives Diverse Treatment Options
|
|
|
|
